Disclosure: Writer holds both MYL and TEVA in actual portfolios (modest by %).
Each of these issues merits watching. Both have similar technical patterns of late. TEVA thinks it is the largest generic drug supplier in the U.S. (it is an Isreali Co.). MYL total sales are about twice those of TEVA, but it does more in Europe and elsewhere. Once news begins to concentrate on "Healthcare" legislation again, such stocks will get more focus. Take a look, and get ahead of the curve.
Eternal vigilance is the price of liberty and the watchword of successful investing